Jane Street’s Xeris Biopharma Holdings XERS Stock Holding History

Jane Street’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,100	Closed	-$103K	–	13159
2025 Q4	$103K	Sell	13,100 -24,600	-65%	-$194K	﹤0.01%	10174
2025 Q3	$307K	Buy	37,700 +19,300	+105%	+$128K	﹤0.01%	8856
2025 Q2	$85.9K	Buy	18,400 +5,300	+40%	+$24.3K	﹤0.01%	9013
2025 Q1	$71.9K	Buy	+13,100	New	+$52.9K	﹤0.01%	8918
2022 Q3	–	Sell	-71,800	Closed	-$111K	–	10590
2022 Q2	$111K	Sell	71,800 -15,000	-17%	-$31.7K	﹤0.01%	8580
2022 Q1	$222K	Sell	86,800 -106,200	-55%	-$259K	﹤0.01%	8892
2021 Q4	$565K	Buy	193,000 +29,600	+18%	+$63.9K	﹤0.01%	7030
2021 Q3	$400K	Sell	163,400 -119,300	-42%	-$346K	﹤0.01%	7684
2021 Q2	$1.15M	Buy	282,700 +105,900	+60%	+$404K	﹤0.01%	5537
2021 Q1	$797K	Buy	176,800 +84,200	+91%	+$454K	﹤0.01%	5896
2020 Q4	$456K	Buy	+92,600	New	+$463K	﹤0.01%	5883

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street's XERS Position: Q1 2026 in Review

Jane Street increased its Xeris Biopharma Holdings (XERS) stake by 308% in Q1 2026, buying an estimated $3.63M and bringing the position to 725,616 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3758.

Jane Street first reported a position in XERS in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.44M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Jane Street held 725,616 shares of Xeris Biopharma Holdings worth $4.21M as of Q1 2026.
Jane Street bought 547,794 Xeris Biopharma Holdings shares in Q1 2026, an estimated $3.63M.
Xeris Biopharma Holdings made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3758 holding.
Jane Street first reported a position in Xeris Biopharma Holdings in Q4 2020 and has held it in 22 quarters since.
Jane Street's Xeris Biopharma Holdings position peaked at $7.44M in Q3 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.